Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

employee benefits 17,929 20,997

Other accrued expenses 4,977 4,014

Income tax payable 13,957 846

Deferred revenue - short term 2,957 2,836

Total current liabilities 54,765 40,470

Non-current income tax payable 4,341 3,958

Deferred income tax - long term 75 75

Deferred revenue - long term 4,441 4,607

Deferred rent - 10

Deferred compensation plan liabilities 2,348 1,893

Commitments and contingencies

Stockholders' equity:

Preferred stock, $.0001 par value per share,

20,000,000 shares authorized, none issued and

outstanding - -

Common stock, $.0001 par value per share;

200,000,000 shares authorized, 53,992,269 and

53,916,298 shares issued and outstanding at

March 31, 2008 and December 31, 2007, respectively 5 5

Additional paid-in capital 423,452 415,229

Accumulated other comprehensive income 2,974 1,604

Retained earnings 353,147 321,202

Total stockholders' equity 779,578 738,040

Total liabilities and stockholders' equity $845,548 $789,053

Gen-Probe Incorporated

Consolidated Statements of Income

(In thousands, except per share data)

Three Months Ended

March 31,


'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LA JOLLA, Calif. , July 29, 2014 /PRNewswire/ ... therapy-based diagnostic and therapeutic company focused on extending the ... have hired Franz Och , Ph.D., an expert ... Chief Data Scientist. Och comes to HLI from Google ... of Google Translate. He will report directly to HLI ...
(Date:7/29/2014)... of researchers has created a new way of ... These surfaces, made by self-assembly of carbon nanotubes, ... including controllable mechanical stiffness and strength, or the ... , "We have demonstrated that mechanical forces can ... three-dimensional microstructures, and that we can independently control ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
(Date:7/29/2014)... SANTA CLARA, Calif. , July 29, 2014 ... research services agreement with FORMA Therapeutics, Inc., to ... capabilities and proprietary fragment-based lead discovery platform for ... are really excited about the opportunity to work ... the fields of epigenetics and protein homeostasis. FORMA ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2
... Products with Herculex(R) XTRA Will Qualify for ... Lower Crop Insurance Rates, ... plant Pioneer(R) brand corn hybrids with the Herculex(R) XTRA,trait, including those ... crop insurance premium reductions in select states in 2009., DuPont ...
... has signed an agreement with AstraZeneca PLC under which Melior’s in-vivo ... activity of selected AstraZeneca compounds. , ... EXTON, ... represents a significant opportunity for Melior to deliver value to AstraZeneca ...
... Product Developed from the VisEn-Merck & Co., Inc. ... Fluorescence Molecular Imaging Agent,Portfolio and Broadens Applications in ... BEDFORD, Mass., Aug. 19 VisEn Medical, ... research through medicine, announced,today the commercial launch of ...
Cached Biology Technology:DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 2DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products 3VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent 2
(Date:7/29/2014)... 29, 2014 Research and Markets  has ... Intelligence (BI) Market 2014-2018" report to their offering. ... The term BI refers to applications and technologies ... analyzing information about a company,s operations. BI help organizations ... business; for example, metrics on sales, production, and internal ...
(Date:7/29/2014)... to the edge of science, Clment Vidal takes on ... and the End: Does our universe have a beginning ... alone in the universe? What is the role of ... science and committed to philosophical rigor, the book presents ... is not an accident, but may well be the ...
(Date:7/29/2014)... UK overseas territory of Ascension Island, one of the ... a renaissance. , Writing in the journal Biodiversity ... and Ascension Island Government Conservation Department report that the ... Atlantic outpost has increased by more than 500 per ... as 24,000 nests are now estimated to be laid ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Book: 'The Beginning and the End' 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... peak in sight fitness peak, that is for ... Lenski, MSU Hannah Distinguished Professor of Microbiology and Molecular Genetics, ... generating more than 50,000 generations. In a paper published in ... author and MSU graduate student in Lenski,s lab, compares it ...
... genetic signature of respiratory syncytial virus (RSV), the leading cause ... key step toward a better understanding of the immune response ... and a tool that could allow physicians to determine the ... from a team at The Research Institute at Nationwide Children,s ...
... may be more able to cope with dry conditions ... and Colorado State University used a computer model to ... the Amazon rainforest may be more able to withstand ... climate models. Many climate models over predict the ...
Cached Biology News:No peak in sight for evolving bacteria 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 2Genetic signature identified for RSV, the leading cause of infant hospitalizations worldwide 3Amazon rainforest more able to withstand drought than previously thought 2
... StabilZyme SELECT Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a saline ... a combination of 0.02% methylisothiazolone and 0.02% ... Stabilizer is a diluent and stabilizer for ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... Stabilizer is a bovine protein-free alternative to ... aqueous solution that contains non-toxic chemicals in ... 6.6 - 7.2, and does not contain ... activity of antibodies and other biomolecules that ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
Biology Products: